

Vijaya R Bhatt

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8384215/publications.pdf>

Version: 2024-02-01

275
papers

4,961
citations

147786

31
h-index

133244

59
g-index

279
all docs

279
docs citations

279
times ranked

7482
citing authors

#	ARTICLE	IF	CITATIONS
1	Usefulness of the Neutrophil-to-Lymphocyte Ratio in Predicting Short- and Long-Term Mortality in Breast Cancer Patients. <i>Annals of Surgical Oncology</i> , 2012, 19, 217-224.	1.5	474
2	Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 926-957.	4.9	451
3	Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 721-749.	4.9	314
4	Pretreatment neutrophil/lymphocyte ratio is superior to platelet/lymphocyte ratio as a predictor of long-term mortality in breast cancer patients. <i>Medical Oncology</i> , 2013, 30, 432.	2.5	206
5	NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 16-27.	4.9	170
6	Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort. <i>Blood Advances</i> , 2018, 2, 923-932.	5.2	114
7	Value of the pretreatment albumin to globulin ratio in predicting long-term mortality in breast cancer patients. <i>American Journal of Surgery</i> , 2013, 206, 764-770.	1.8	103
8	The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort. <i>Blood Advances</i> , 2018, 2, 1765-1772.	5.2	100
9	Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission. <i>Blood Advances</i> , 2019, 3, 1826-1836.	5.2	89
10	Ipilimumab-Induced Hypophysitis and Uveitis in a Patient With Metastatic Melanoma and a History of Ipilimumab-Induced Skin Rash. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 1077-1081.	4.9	66
11	Impact of hospital volume on outcomes of patients undergoing chemotherapy for acute myeloid leukemia: a matched cohort study. <i>Blood</i> , 2015, 125, 3359-3360.	1.4	59
12	Early mortality and overall survival of acute myeloid leukemia based on facility type. <i>American Journal of Hematology</i> , 2017, 92, 764-771.	4.1	58
13	Invasive fungal infections in acute leukemia. <i>Therapeutic Advances in Hematology</i> , 2011, 2, 231-247.	2.5	56
14	Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts. <i>Lancet Haematology</i> , 2020, 7, e601-e612.	4.6	56
15	Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international study. <i>Leukemia</i> , 2020, 34, 3149-3160.	7.2	54
16	Venous thromboembolism in patients with hematologic malignancy and thrombocytopenia. <i>American Journal of Hematology</i> , 2016, 91, E468-E472.	4.1	48
17	Eculizumab in Transplant-Associated Thrombotic Microangiopathy. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2017, 23, 175-180.	1.7	48
18	Reversal of Anticoagulation and Management of Bleeding in Patients on Anticoagulants. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2017, 23, 410-415.	1.7	47

#	ARTICLE	IF	CITATIONS
19	Geriatric assessment in older alloHCT recipients: association of functional and cognitive impairment with outcomes. <i>Blood Advances</i> , 2020, 4, 2810-2820.	5.2	47
20	Venous Thromboembolism in COVID-19: Towards an Ideal Approach to Thromboprophylaxis, Screening, and Treatment. <i>Current Cardiology Reports</i> , 2020, 22, 52.	2.9	47
21	L-asparaginase and venous thromboembolism in acute lymphocytic leukemia. <i>Future Oncology</i> , 2015, 11, 2459-2470.	2.4	45
22	Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2016, 22, 12-20.	1.7	45
23	Redox-responsive nanoplatform for codelivery of miR-519c and gemcitabine for pancreatic cancer therapy. <i>Science Advances</i> , 2020, 6, .	10.3	42
24	Differentiating malignant hypertension-induced thrombotic microangiopathy from thrombotic thrombocytopenic purpura. <i>Therapeutic Advances in Hematology</i> , 2015, 6, 97-102.	2.5	40
25	Utilization of initial chemotherapy for newly diagnosed acute myeloid leukemia in the United States. <i>Blood Advances</i> , 2018, 2, 1277-1282.	5.2	37
26	Brain Metastasis in Patients With Non-Small-Cell Lung Cancer and Epidermal Growth Factor Receptor Mutations. <i>Journal of Clinical Oncology</i> , 2013, 31, 3162-3164.	1.6	36
27	Primary mediastinal large B-cell lymphoma. <i>Cancer Treatment Reviews</i> , 2015, 41, 476-485.	7.7	36
28	Socioeconomic and health system factors associated with lower utilization of hematopoietic cell transplantation in older patients with acute myeloid leukemia. <i>Bone Marrow Transplantation</i> , 2018, 53, 1288-1294.	2.4	36
29	Composite GRFS and CRFS Outcomes After Adult Alternative Donor HCT. <i>Journal of Clinical Oncology</i> , 2020, 38, 2062-2076.	1.6	36
30	Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia. <i>Blood Advances</i> , 2022, 6, 339-357.	5.2	35
31	Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1459-1468.	2.0	35
32	THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2016, 9, e2017019.	1.3	34
33	Fondaparinux-associated heparin-induced thrombocytopenia. <i>European Journal of Haematology</i> , 2013, 91, 437-441.	2.2	33
34	Epidermal Growth Factor Receptor Mutational Status and Brain Metastases in Non-Small-Cell Lung Cancer. <i>Journal of Global Oncology</i> , 2017, 3, 208-217.	0.5	33
35	Hematopoietic Cell Transplantation, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 599-634.	4.9	33
36	Therapy-related myeloid neoplasms after autologous hematopoietic stem cell transplantation in lymphoma patients. <i>Cancer Biology and Therapy</i> , 2013, 14, 1077-1088.	3.4	31

#	ARTICLE	IF	CITATIONS
37	Central Nervous System Complications and Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 606-611.	0.4	29
38	Acute promyelocytic leukemia during pregnancy: a systematic analysis of outcome. <i>Leukemia and Lymphoma</i> , 2016, 57, 616-622.	1.3	29
39	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2020 Treatment of Chronic GVHD Report. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 729-737.	1.2	29
40	Chemotherapy use in stage III colon cancer: a National Cancer Database analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2015, 7, 244-251.	3.2	28
41	Systemic therapy in stage IV pancreatic cancer: a population-based analysis using the National Cancer Data Base. <i>Therapeutic Advances in Medical Oncology</i> , 2015, 7, 198-205.	3.2	28
42	Secondary acute lymphoblastic leukemia is an independent predictor of poor prognosis. <i>Leukemia Research</i> , 2015, 39, 1342-1346.	0.8	28
43	Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR. <i>Leukemia</i> , 2021, 35, 2076-2085.	7.2	28
44	Characteristics and survival of BCR/ABL negative chronic myeloid leukemia: a retrospective analysis of the Surveillance, Epidemiology and End Results database. <i>Therapeutic Advances in Hematology</i> , 2015, 6, 308-312.	2.5	27
45	Mortality, length of stay, and health care costs of febrile neutropenia-related hospitalizations among patients with breast cancer in the United States. <i>Supportive Care in Cancer</i> , 2015, 23, 615-617.	2.2	27
46	Management and Outcome of Heparin-Induced Thrombocytopenia in Pregnancy: A Systematic Review. <i>Cardiovascular and Hematological Agents in Medicinal Chemistry</i> , 2015, 13, 92-97.	1.0	27
47	Risk Factors, Therapy and Survival Outcomes of Small Cell and Large Cell Neuroendocrine Carcinoma of Urinary Bladder. <i>Rare Tumors</i> , 2014, 6, 10-14.	0.6	25
48	Is complement blockade an acceptable therapeutic strategy for hematopoietic cell transplant-associated thrombotic microangiopathy?. <i>Bone Marrow Transplantation</i> , 2017, 52, 352-356.	2.4	25
49	Allogeneic transplant and CAR-T therapy after autologous transplant failure in DLBCL: a noncomparative cohort analysis. <i>Blood Advances</i> , 2022, 6, 486-494.	5.2	25
50	Risk of Second Primary Malignancies in Patients With Follicular Lymphoma: A United States Population-based Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 569-574.	0.4	24
51	Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research. <i>Haematologica</i> , 2020, 105, 1329-1338.	3.5	23
52	Risk of secondary solid malignancies after allogeneic hematopoietic stem cell transplantation and preventive strategies. <i>Future Oncology</i> , 2015, 11, 3175-3185.	2.4	22
53	Clinicopathologic features and management of blastoid variant of mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 2759-2767.	1.3	22
54	Activity of single-agent decitabine in atypical chronic myeloid leukemia. <i>Journal of Oncology Pharmacy Practice</i> , 2016, 22, 790-794.	0.9	22

#	ARTICLE	IF	CITATIONS
55	Incidence trend of esophageal squamous cell carcinoma: an analysis of Surveillance Epidemiology, and End Results (SEER) database. <i>Cancer Causes and Control</i> , 2015, 26, 159-161.	1.8	21
56	Mortality Patterns Among Recipients of Autologous Hematopoietic Stem Cell Transplantation for Lymphoma and Myeloma in the Past Three Decades. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 409-415.e1.	0.4	21
57	Personalizing therapy for older adults with acute myeloid leukemia: Role of geriatric assessment and genetic profiling. <i>Cancer Treatment Reviews</i> , 2019, 75, 52-61.	7.7	21
58	Meta-analysis on efficacy and safety of new oral anticoagulants for venous thromboembolism prophylaxis in overweight and obese postarthroplasty patients. <i>Blood Coagulation and Fibrinolysis</i> , 2015, 26, 635-642.	1.0	20
59	Role of radiation therapy in primary mediastinal large B-cell lymphoma in rituximab era: A US population-based analysis. <i>American Journal of Hematology</i> , 2015, 90, 1052-1054.	4.1	20
60	Management of Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 245-252.	0.4	20
61	Reduced-intensity conditioning allogeneic hematopoietic-cell transplantation for older patients with acute myeloid leukemia. <i>Therapeutic Advances in Hematology</i> , 2016, 7, 131-141.	2.5	20
62	Heparin Reexposure in Patients With a History of Heparin-Induced Thrombocytopenia. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2015, 21, 626-631.	1.7	19
63	Usefulness of Charlson Comorbidity Index to Predict Early Mortality and Overall Survival in Older Patients With Acute Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 804-812.e8.	0.4	19
64	Impact of Previously Unrecognized HLA Mismatches Using Ultrahigh Resolution Typing in Unrelated Donor Hematopoietic Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2021, 39, 2397-2409.	1.6	19
65	Secondary Polycythemia and the Risk of Venous Thromboembolism. <i>Journal of Clinical Medicine Research</i> , 2014, 6, 395-7.	1.2	19
66	Hematopoietic Stem Cell Transplantation for Non-Hodgkin Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2014, 28, 1073-1095.	2.2	18
67	Brentuximab vedotin desensitization in a patient with refractory Hodgkin's lymphoma. <i>European Journal of Haematology</i> , 2015, 95, 361-364.	2.2	18
68	Risk of second primary malignancies and survival of adult patients with polycythemia vera: A United States population-based retrospective study. <i>Leukemia and Lymphoma</i> , 2016, 57, 129-133.	1.3	18
69	Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. <i>Blood Advances</i> , 2020, 4, 3180-3190.	5.2	18
70	Age is no barrier for adults undergoing HCT for AML in CR1: contemporary CIBMTR analysis. <i>Bone Marrow Transplantation</i> , 2022, 57, 911-917.	2.4	18
71	ST-Segment Elevation Myocardial Infarction (STEMI) and Pulmonary Embolism in a Hemophilia A Patient Receiving Emicizumab and recombinant Activated Factor VII. <i>Haemophilia</i> , 2020, 26, e5-e8.	2.1	17
72	Allogeneic Stem Cell Transplantation for Philadelphia Chromosome-Positive Acute Myeloid Leukemia. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 963-968.	4.9	16

#	ARTICLE	IF	CITATIONS
73	Allogeneic Stem Cell Transplantation for Non-Hodgkin Lymphoma. <i>Current Hematologic Malignancy Reports</i> , 2016, 11, 196-207.	2.3	16
74	Clinicopathologic features, management and outcomes of blastoid variant of mantle cell lymphoma: a Nebraska Lymphoma Study Group Experience. <i>Leukemia and Lymphoma</i> , 2016, 57, 1327-1334.	1.3	16
75	Atypical chronic myeloid leukemia: a rare entity with management challenges. <i>Future Oncology</i> , 2018, 14, 177-185.	2.4	16
76	Breast cancer knowledge, attitudes and practices among Nepalese women. <i>European Journal of Cancer Care</i> , 2011, 20, 810-817.	1.5	15
77	Patterns of care and clinical outcomes of patients with newly diagnosed acute myeloid leukemia presenting with hyperleukocytosis who do not receive intensive chemotherapy. <i>Leukemia and Lymphoma</i> , 2020, 61, 1220-1225.	1.3	15
78	Allogeneic Transplantation to Treat Therapy-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Adults. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 923.e1-923.e12.	1.2	15
79	Racial Differences in the Overall Survival of Hairy-Cell Leukemia in the United States: A Population-Based Analysis of the Surveillance, Epidemiology, and End Results Database. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 484-488.	0.4	14
80	Use of hematopoietic cell transplantation in younger patients with acute myeloid leukemia: A National Cancer Database Study. <i>Bone Marrow Transplantation</i> , 2018, 53, 873-879.	2.4	14
81	Impact of T Cell Dose on Outcome of T Cell-Replete HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1875-1883.	2.0	14
82	Treatment patterns and outcomes of octogenarian patients with acute myeloid leukemia. <i>American Journal of Hematology</i> , 2019, 94, E169-E172.	4.1	14
83	Breaking the Age Barrier: Physicians' Perceptions of Candidacy for Allogeneic Hematopoietic Cell Transplantation in Older Adults. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 617.e1-617.e7.	1.2	14
84	Extranodal natural killer/T cell lymphoma, nasal type presenting as a palatal perforation and naso-oral fistula. <i>BMJ Case Reports</i> , 2011, 2011, bcr1120103511-bcr1120103511.	0.5	13
85	Therapy of Core Binding Factor Acute Myeloid Leukemia: Incremental Improvements Toward Better Long-Term Results. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 153-158.	0.4	13
86	AUTOIMMUNE CYTOPENIAS IN CHRONIC LYMPHOCYTIC LEUKEMIA, FACTS AND MYTHS. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2013, 5, e2013068.	1.3	13
87	Leukemic transformation in essential thrombocythemia. <i>Future Oncology</i> , 2014, 10, 2593-2602.	2.4	13
88	Leukemic Diffuse Large B-Cell Lymphoma in a Patient With Myeloproliferative Disorder. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 281-287.	4.9	13
89	Time to Insurance Approval in Private and Public Payers Does Not Influence Survival in Patients Who Undergo Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1117-1124.	2.0	13
90	Central nervous system complications after allogeneic hematopoietic stem cell transplantation. <i>Future Oncology</i> , 2017, 13, 2297-2312.	2.4	13

#	ARTICLE	IF	CITATIONS
91	An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis. <i>Bone Marrow Transplantation</i> , 2021, 56, 3068-3077.	2.4	13
92	Chronic Graft-versus-Host Disease, Nonrelapse Mortality, and Disease Relapse in Older versus Younger Adults Undergoing Matched Allogeneic Peripheral Blood Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Analysis. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 34-42.	1.2	13
93	Preferences of adults with cancer for systemic cancer treatment: do preferences differ based on age?. <i>Future Oncology</i> , 2022, 18, 311-321.	2.4	13
94	Effect of Adjuvant Radiotherapy on Survival in Patients with Locoregional Urothelial Malignancies of the Upper Urinary Tract. <i>Anticancer Research</i> , 2016, 36, 4051-5.	1.1	13
95	Unilateral orbital pain and eyelid swelling in a 46-year-old woman: orbital metastasis of occult invasive lobular carcinoma of breast masquerading orbital pseudotumour. <i>BMJ Case Reports</i> , 2011, 2011, bcr1220103580-bcr1220103580.	0.5	12
96	Sorafenib in Relapsed AML With FMS-Like Receptor Tyrosine Kinase-3 Internal Tandem Duplication Mutation. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 508-514.	4.9	12
97	Effect of smoking on survival from non-small cell lung cancer: a retrospective Veterans Affairs Central Cancer Registry (VACCR) cohort analysis. <i>Medical Oncology</i> , 2015, 32, 339.	2.5	12
98	Clinicopathologic characteristics and management trends of cutaneous invasive and <i>in situ</i> melanoma in older patients: a retrospective analysis of the National Cancer Data Base. <i>Therapeutic Advances in Medical Oncology</i> , 2015, 7, 4-11.	3.2	12
99	GRFS and CRFS in alternative donor hematopoietic cell transplantation for pediatric patients with acute leukemia. <i>Blood Advances</i> , 2019, 3, 1441-1449.	5.2	12
100	Novel Treatment Paradigms in Acute Myeloid Leukemia. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 506-514.	4.7	12
101	Ixazomib for Treatment of Refractory Chronic Graft-versus-Host Disease: A Chronic GVHD Consortium Phase II Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1612-1619.	2.0	12
102	Medical and economic burden of heparin-induced thrombocytopenia: A retrospective nationwide inpatient sample (NIS) study. <i>Journal of Hospital Medicine</i> , 2017, 12, 94-97.	1.4	12
103	Lack of "Weekend Effect" on Mortality for Pulmonary Embolism Admissions in 2011: Data from Nationwide Inpatient Sample. <i>International Journal of Cardiology</i> , 2015, 180, 151-153.	1.7	11
104	Initial therapy for acute myeloid leukemia in older patients: principles of care. <i>Leukemia and Lymphoma</i> , 2018, 59, 29-41.	1.3	11
105	Outcomes of therapy with venetoclax combined with a hypomethylating agent in favorable-risk acute myeloid leukemia. <i>American Journal of Hematology</i> , 2021, 96, E59-E63.	4.1	11
106	A case of toxic epidermal necrolysis caused by trimethoprim-sulfamethoxazole. <i>BMJ Case Reports</i> , 2014, 2014, bcr2013203163-bcr2013203163.	0.5	11
107	Incidence of breast cancer among female survivors of Hodgkin lymphoma: a US-population-based trend analysis from 1973 to 2011. <i>Blood</i> , 2015, 126, 1861-1863.	1.4	10
108	Hematopoietic Cell Transplantation for Myelodysplastic Syndromes. <i>Journal of Oncology Practice</i> , 2016, 12, 786-792.	2.5	10

#	ARTICLE	IF	CITATIONS
109	Secondary acute myeloid leukemia in survivors of Hodgkin lymphoma. <i>Future Oncology</i> , 2016, 12, 1565-1575.	2.4	10
110	Application of immunophenotypic analysis in distinguishing chronic myelomonocytic leukemia from reactive monocytosis. <i>Cytometry Part B - Clinical Cytometry</i> , 2018, 94, 901-909.	1.5	10
111	Cancer in older adults: understanding cause and effects of chemotherapy-related toxicities. <i>Future Oncology</i> , 2019, 15, 2557-2560.	2.4	10
112	Effects of Obesity on Overall Survival of Adults With Acute Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e131-e136.	0.4	10
113	Treatment Strategies for Therapy-related Acute Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 147-155.	0.4	10
114	Perforation in a patient with stercoral colitis and diverticulosis: who did it?. <i>Journal of Community Hospital Internal Medicine Perspectives</i> , 2014, 4, 22898.	0.8	9
115	Before it crumbles: Fulminant Hepatic Failure secondary to Hodgkin's Lymphoma. <i>Journal of Community Hospital Internal Medicine Perspectives</i> , 2014, 4, 25821.	0.8	9
116	Lung cancer trends: smoking, obesity, and sex assessed in the Staten Island University's lung cancer patients. <i>International Journal of General Medicine</i> , 2014, 7, 333.	1.8	9
117	Prognostic Implications of Chromosome 17 Abnormalities in the Context of Monosomal Karyotype in Patients With Acute Myeloid Leukemia and Complex Cytogenetics. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 163-171.	0.4	9
118	Systemic Anaplastic Lymphoma Kinase-positive Anaplastic Large Cell Lymphoma: A Population-based Analysis of Incidence and Survival. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 201-206.	0.4	9
119	Second primary malignancy in acute promyelocytic leukemia: a Surveillance, Epidemiology and End Results database study. <i>Future Oncology</i> , 2017, 13, 1455-1457.	2.4	9
120	Renal Cancer in Recipients of Kidney Transplant. <i>Rare Tumors</i> , 2017, 9, 9-13.	0.6	9
121	Prevalence and effects of polypharmacy on overall survival in acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2020, 61, 1702-1708.	1.3	9
122	Early mortality and overall survival in acute promyelocytic leukemia: do real-world data match results of the clinical trials?. <i>Leukemia and Lymphoma</i> , 2021, 62, 1949-1957.	1.3	9
123	Risk of second primary malignancies in a population-based study of adult patients with essential thrombocythemia. <i>World Journal of Clinical Oncology</i> , 2016, 7, 324.	2.3	9
124	Integrating geriatric assessment and genetic profiling to personalize therapy selection in older adults with acute myeloid leukemia. <i>Journal of Geriatric Oncology</i> , 2022, 13, 871-874.	1.0	9
125	Electrophysiological Measure of Impaired Information Processing in Drivers with Hematological Malignancy. <i>Transportation Research Record</i> , 2018, 2672, 64-73.	1.9	8
126	New Oral Anticoagulants for the Management of Heparin Induced Thrombocytopenia: A Focused Literature Review. <i>Cardiovascular and Hematological Agents in Medicinal Chemistry</i> , 2015, 13, 87-91.	1.0	8

#	ARTICLE	IF	CITATIONS
127	Prognostic Implication of Chromosome 17 Abnormalities in the Context of Monosomal Karyotype (MK) in Patients with Acute Myeloid Leukemia (AML) and Complex Cytogenetics. <i>Blood</i> , 2011, 118, 1495-1495.	1.4	8
128	Optimal graft source for allogeneic hematopoietic stem cell transplant: bone marrow or peripheral blood?. <i>Future Oncology</i> , 2016, 12, 1823-1832.	2.4	7
129	Effects of center type and socioeconomic factors on early mortality and overall survival of diffuse large B-cell lymphoma. <i>Future Oncology</i> , 2019, 15, 2113-2124.	2.4	7
130	Cardiac tamponade in acute pancreatitis. <i>BMJ Case Reports</i> , 2011, 2011, bcr0820103287-bcr0820103287.	0.5	7
131	Integrating Geriatric Assessment and Genetic Profiling to Personalize Therapy Selection in Older Adults with Acute Myeloid Leukemia (AML). <i>Blood</i> , 2019, 134, 120-120.	1.4	7
132	Mycophenolate Mofetil (MMF)-Induced Colitis. <i>Blood</i> , 2016, 128, 4795-4795.	1.4	7
133	Emerging Therapy Options in Heparin-Induced Thrombocytopenia. <i>Cardiovascular and Hematological Agents in Medicinal Chemistry</i> , 2014, 12, 50-58.	1.0	6
134	Demographic and other characteristics of nodal non-Hodgkinâ€™s lymphoma managed in academic <i>versus</i> non-academic centers. <i>Therapeutic Advances in Hematology</i> , 2015, 6, 223-227.	2.5	6
135	Early mortality and survival in older adults with acute myeloid leukemia. <i>International Journal of Hematologic Oncology</i> , 2017, 6, 61-63.	1.6	6
136	Synchronous or Metachronous Hairy Cell Leukemia and Chronic Lymphocytic Leukemia: A Case Series and Literature Review. <i>Frontiers in Oncology</i> , 2017, 6, 270.	2.8	6
137	Allogeneic Hematopoietic Stem Cell Transplantation Following the Use of Hypomethylating Agents among Patients with Relapsed or Refractory AML: Findings from an International Retrospective Study. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1754-1758.	2.0	6
138	Understanding patients' values and priorities in selecting cancer treatments: Developing a therapy preference scale. <i>Journal of Geriatric Oncology</i> , 2019, 10, 677-679.	1.0	6
139	Immunotherapeutic options for management of relapsed or refractory B-cell acute lymphoblastic leukemia: how to select newly approved agents?. <i>Leukemia and Lymphoma</i> , 2020, 61, 7-17.	1.3	6
140	Effects of Distance From Academic Cancer Center on Overall Survival of Acute Myeloid Leukemia: Retrospective Analysis of Treated Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e685-e690.	0.4	6
141	Survival of Older Adults With Newly Diagnosed Acute Myeloid Leukemia: Effect of Using Multiagent Versus Single-agent Chemotherapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e239-e258.	0.4	6
142	Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 2108-2117.	2.4	6
143	Overall Survival (OS) of Acute Myeloid Leukemia (AML) Treated at Academic Center (AC) Versus Non-Academic Center (NAC). <i>Blood</i> , 2015, 126, 533-533.	1.4	6
144	Concurrent Acute Monoblastic Leukemia and Multiple Myeloma in a 66-Year-Old Chemotherapy-Naive Woman. <i>World Journal of Oncology</i> , 2014, 5, 68-71.	1.5	6

#	ARTICLE	IF	CITATIONS
145	Sarcoidosis and antiphospholipid syndrome: A systematic review of cases. North American Journal of Medical Sciences, 2015, 7, 379.	1.7	6
146	Recurrent imatinib-induced hepatotoxicity in a chronic myeloid leukaemia patient successfully managed with prednisone. BMJ Case Reports, 2011, 2011, bcr1120103516-bcr1120103516.	0.5	5
147	A retrospective analysis of reported errata in five leading medical journals in 2012. Journal of Community Hospital Internal Medicine Perspectives, 2014, 4, 25738.	0.8	5
148	Autoimmune Neutropenia in Multiple Myeloma and the Role of Clonal T-Cell Expansion: Evidence of Cross-Talk Between B-Cell and T-Cell Lineages?. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, e19-e23.	0.4	5
149	Trends in bloodâ€product transfusion among inpatients in the United States from 2002 to 2011: Data from the Nationwide Inpatient Sample. Journal of Hospital Medicine, 2014, 9, 800-801.	1.4	5
150	Fibroid degeneration in a postmenopausal woman presenting as an acute abdomen. Journal of Community Hospital Internal Medicine Perspectives, 2015, 5, 25917.	0.8	5
151	Survival of de novo and secondary acute promyelocytic leukemia: a propensity-matched analysis of the SEER database. Leukemia and Lymphoma, 2016, 57, 385-391.	1.3	5
152	Neurophysiologic and ophthalmic markers of chemotherapy-related cognitive impairment in patients diagnosed with hematologic cancer: A feasibility study. Journal of the Neurological Sciences, 2020, 410, 116644.	0.6	5
153	Nanoformulation design and therapeutic potential of a novel tubulin inhibitor in pancreatic cancer. Journal of Controlled Release, 2021, 329, 585-597.	9.9	5
154	Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and <i>KMT2A</i>-rearranged AML. Blood Advances, 2022, 6, 828-847.	5.2	5
155	Cognitive Impairment Is Associated with Inferior Survival and Increased Non-Relapse Mortality in Older Allogeneic Hematopoietic Cell Transplant (alloHCT) Recipients: A Multicenter Retrospective Study. Blood, 2019, 134, 4606-4606.	1.4	5
156	The Use of Hypomethylating Agents (HMAs) in Patients with Relapsed and Refractory Acute Myeloid Leukemia (RR-AML): Clinical Outcomes and Their Predictors in a Large International Patient Cohort. Blood, 2016, 128, 1063-1063.	1.4	5
157	Secondary Polycythemia and the Risk of Venous Thromboembolism (VTE) Among Hospitalized Patients in the United States. Blood, 2016, 128, 1427-1427.	1.4	5
158	A Primary Care Approach to Myelodysplastic Syndromes. Korean Journal of Family Medicine, 2014, 35, 111.	1.2	5
159	Benign and Malignant Hematological Manifestations of Chronic Hepatitis C Virus Infection. International Journal of Preventive Medicine, 2014, 5, S179-92.	0.4	5
160	Safety and efficacy of preoperative sorafenib therapy in facilitating cytoreductive surgery in renal cell carcinoma. Future Oncology, 2014, 10, 703-706.	2.4	4
161	Factors associated with receipt of hematopoietic cell transplantation for acute lymphoblastic leukemia. Future Oncology, 2018, 14, 1253-1260.	2.4	4
162	Intensity of chemotherapy for the initial management of newly diagnosed acute myeloid leukemia in older patients. Future Oncology, 2019, 15, 1989-1995.	2.4	4

#	ARTICLE	IF	CITATIONS
163	Genetics of HLA Peptide Presentation and Impact on Outcomes in HLA-Matched Allogeneic Hematopoietic Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 591-599.	1.2	4
164	Overall Survival (OS) of Acute Lymphoblastic Leukemia (ALL) Is Better When Initial Therapy Is Administered in Academic Hospitals (AH) Versus Non-Academic Hospitals (NAH): A Retrospective Analysis of the National Cancer Data Base (NCDB). <i>Blood</i> , 2015, 126, 268-268.	1.4	4
165	Fondaparinux for Management of Heparin-induced Thrombocytopenia after Cardiovascular Intervention: A Systematic Review. <i>Cardiovascular and Hematological Agents in Medicinal Chemistry</i> , 2015, 13, 82-86.	1.0	4
166	Characteristics, Treatment Patterns and Outcomes Among Newly Diagnosed Patients (pts) with Acute Myeloid Leukemia (AML) Who Present with Hyperleukocytosis: Findings from a Large International Patient Cohort. <i>Blood</i> , 2018, 132, 4040-4040.	1.4	4
167	Seasonal variation of immune thrombocytopenic purpura related hospitalizations among adults in the USA: analysis of the nationwide inpatient sample database. <i>Therapeutic Advances in Hematology</i> , 2015, 6, 217-218.	2.5	3
168	Survival of Subcutaneous Panniculitis-Like T-Cell Lymphoma and Peripheral T-Cell Lymphoma Not Otherwise Specified: A Propensity-Matched Analysis of the Surveillance, Epidemiology, and End Results Database. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 373-378.	0.4	3
169	Outcomes of haploidentical transplant compared with matched donor allogeneic stem cell transplant. <i>Future Oncology</i> , 2017, 13, 935-944.	2.4	3
170	Use of Digital Technology to Optimize Functional Status in an Older Patient With Myelodysplastic Syndrome. <i>Journal of Oncology Practice</i> , 2017, 13, 141-142.	2.5	3
171	A precision medicine approach to management of acute myeloid leukemia in older adults. <i>Current Opinion in Oncology</i> , 2020, 32, 650-655.	2.4	3
172	Advances and unanswered questions in management of acute myeloid leukemia in older adults: A glimpse into the future. <i>Journal of Geriatric Oncology</i> , 2021, 12, 980-984.	1.0	3
173	Port-a-cath embolisation to pulmonary artery. <i>BMJ Case Reports</i> , 2011, 2011, bcr0620114303-bcr0620114303.	0.5	3
174	Heparin Re-Exposure in Patients with Heparin-Induced Thrombocytopenia (HIT). <i>Blood</i> , 2014, 124, 4265-4265.	1.4	3
175	Chemotherapy in Elderly Patients with Acute Myeloid Leukemia (AML): Analysis of Socioeconomic Factors Using National Cancer Data Base (NCDB). <i>Blood</i> , 2014, 124, 5267-5267.	1.4	3
176	Near Misdiagnosis of Glioblastoma as Primary Central Nervous System Lymphoma. <i>Journal of Clinical Medicine Research</i> , 2014, 6, 299-301.	1.2	3
177	A prospective biomarker analysis of alvocidib followed by cytarabine and mitoxantrone in MCL-1-dependent relapsed/refractory acute myeloid leukemia. <i>Blood Cancer Journal</i> , 2021, 11, 175.	6.2	3
178	Blast MRD CML 1 Trial: Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease (MRD) in Chronic Myeloid Leukemia (CML)- a Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease: A Trial of the ECOG-ACRIN Cancer Research Group (EA9171). <i>Blood</i> , 2020, 136, 1-1.	1.4	3
179	Effect of Age and Socioeconomic Factors in the Utilization of Chemotherapy in Acute Lymphoblastic Leukemia (ALL): A SEER Database Study of 16,196 Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, e907-e914.	0.4	3
180	Acute mesenteric ischemia: a sequela of abdominal aortography. <i>Journal of Community Hospital Internal Medicine Perspectives</i> , 2014, 4, 22894.	0.8	2

#	ARTICLE	IF	CITATIONS
181	Sorafenib in squamous cell carcinoma of the head and neck: molecular basis and potential role. <i>Future Oncology</i> , 2014, 10, 17-20.	2.4	2
182	Seasonal variation in the presentation of thyroid cancer in the USA: an analysis of the Surveillance, Epidemiology and End Results Registry. <i>Cancer Causes and Control</i> , 2014, 25, 1583-1585.	1.8	2
183	Targeted therapy in metastatic colon cancer. <i>Future Oncology</i> , 2014, 10, 707-711.	2.4	2
184	Reversible bone marrow aplasia induced by pegylated interferon- α 2a therapy in a patient with primary myelofibrosis. <i>Journal of Oncology Pharmacy Practice</i> , 2014, 20, 386-392.	0.9	2
185	Treatment-related acute myeloid leukemia in a chronic lymphocytic leukemia patient: role of fludarabine?. <i>Therapeutic Advances in Hematology</i> , 2015, 6, 88-92.	2.5	2
186	Second primary malignancies in Waldenstrom's macroglobulinemia: a US population-based study. <i>Cancer Causes and Control</i> , 2015, 26, 645-647.	1.8	2
187	Initial management of immune thrombocytopenia in adults based on risk stratification. <i>Postgraduate Medical Journal</i> , 2019, 95, 558-562.	1.8	2
188	Development and validation of the Therapy Preference Scale to understand patients' systemic cancer treatment preferences. <i>Future Oncology</i> , 2021, 17, 37-44.	2.4	2
189	Accelerated arterial and venous clots in a young pregnant woman: a saga of thrombotic storm. <i>BMJ Case Reports</i> , 2013, 2013, bcr2013009776-bcr2013009776.	0.5	2
190	Safety and Efficacy of Enoxaparin Prophylaxis in Adults Receiving Peg-Asparaginase Containing Induction Regimens for Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2016, 128, 5154-5154.	1.4	2
191	Center Effect and Socioeconomic Determinants of Overall Survival (OS) of Diffuse Large B Cell Lymphoma (DLBCL). <i>Blood</i> , 2016, 128, 5949-5949.	1.4	2
192	Conditional survival estimates for small cell lung cancer receiving prophylactic cranial irradiation in the U.S. (1988-1997).. <i>Journal of Clinical Oncology</i> , 2015, 33, 7577-7577.	1.6	2
193	Overall survival (OS) of acute promyelocytic leukemia (APL) treated in academic (AC) versus non academic (NAC) centers.. <i>Journal of Clinical Oncology</i> , 2016, 34, e18142-e18142.	1.6	2
194	Disparity in Utilization of Multiagent Therapy for Acute Promyelocytic Leukemia in the United States. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 319-325.	0.4	2
195	A 20-year-old Chinese man with recurrent hypokalemic periodic paralysis and delayed diagnosis. <i>BMJ Case Reports</i> , 2012, 2012, bcr0120125541-bcr0120125541.	0.5	2
196	T cell acute lymphoblastic leukaemia presenting with sudden onset right oculomotor nerve palsy with normal neuroradiography and cerebrospinal fluid studies. <i>BMJ Case Reports</i> , 2012, 2012, bcr0120125685-bcr0120125685.	0.5	2
197	IgM Myeloma or Waldenstrom's Macroglobulinemia Is the Big Question?. <i>M&D</i> , 2014, 9, 72-5.	0.1	2
198	Impact of Insurance on Overall Survival in Acute Lymphoblastic Leukemia: A SEER Database Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, , .	0.4	2

#	ARTICLE	IF	CITATIONS
199	Natural Killer Cell Alloreactivity Predicted By Killer Cell Immunoglobulin-Like Receptor Ligand Mismatch Does Not Impact Engraftment in Umbilical Cord Blood and Haploidentical Stem Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 483.e1-483.e7.	1.2	2
200	Right upper quadrant pain and mass in a 41-year-old previously healthy man: a presenting feature of HIV-associated extranodal diffuse large B cell lymphoma with cardiac involvement. <i>BMJ Case Reports</i> , 2012, 2012, bcr1120115217-bcr1120115217.	0.5	1
201	Combination therapy with bevacizumab and temsirolimus in squamous cell carcinoma of the head and neck. <i>Oral Oncology</i> , 2013, 49, e25.	1.5	1
202	Seasonal and regional variation of thrombotic thrombocytopenic purpura in the United States: Insights from the nationwide inpatient sample. <i>American Journal of Hematology</i> , 2015, 90, E24.	4.1	1
203	An Algorithmic Approach to Management of Venous Thromboembolism. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2017, 23, 511-517.	1.7	1
204	Staging and restaging patients with lymphoma – a better approach?. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 527-528.	27.6	1
205	Mantle Cell Lymphoma. , 2018, , 1298-1308.e2.		1
206	Allogeneic Hematopoietic Cell Transplantation in Younger Patients With Acute Myeloid Leukemia. <i>Journal of Oncology Practice</i> , 2019, 15, 321-322.	2.5	1
207	Modified Papanicolaou staining for oral swab samples stored long term. <i>Biotechnic and Histochemistry</i> , 2020, 96, 1-5.	1.3	1
208	Effect of geriatric assessment (GA) and genetic profiling on overall survival (OS) of older adults with acute myeloid leukemia (AML).. <i>Journal of Clinical Oncology</i> , 2021, 39, 7021-7021.	1.6	1
209	Incidence and Overall Survival of Therapy Related Myeloid Neoplasm in United States. <i>Blood</i> , 2016, 128, 3992-3992.	1.4	1
210	Long-term outcomes of rituximab use prior to autologous stem cell transplant (ASCT) in low-grade follicular lymphoma (FL) at the time of first progression.. <i>Journal of Clinical Oncology</i> , 2015, 33, 7036-7036.	1.6	1
211	Hematopoietic cell transplantation (HCT) in older patients with acute myeloid leukemia (AML).. <i>Journal of Clinical Oncology</i> , 2016, 34, e18026-e18026.	1.6	1
212	Effect of EGFR mutations on outcomes in NSCLC with brain metastases.. <i>Journal of Clinical Oncology</i> , 2016, 34, e20644-e20644.	1.6	1
213	Practice patterns and clinical outcomes of therapy-related acute myeloid leukemia (TAML) in the US.. <i>Journal of Clinical Oncology</i> , 2017, 35, e18139-e18139.	1.6	1
214	Understanding therapy preferences of cancer patients with the use of therapy preference scale.. <i>Journal of Clinical Oncology</i> , 2020, 38, e24186-e24186.	1.6	1
215	Financial Impact of Tumor Lysis Syndrome Among Inpatients in the United States. <i>Blood</i> , 2014, 124, 5966-5966.	1.4	1
216	Impact of Leukapheresis and Time to Chemotherapy on Outcomes of Newly Diagnosed Patients (pts) with Acute Myeloid Leukemia (AML) Presenting with Hyperleukocytosis: An Analysis from a Large International Patient Cohort. <i>Blood</i> , 2018, 132, 1428-1428.	1.4	1

#	ARTICLE	IF	CITATIONS
217	Therapy preference scale: A novel questionnaire to understand patients'™ preferences of cancer treatment.. Journal of Clinical Oncology, 2019, 37, e23179-e23179.	1.6	1
218	Minimal Toxicity Seen When Pembrolizumab Is Added to Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease: Early Results from an Ongoing Phase II Trial (ECOG-ACRIN EA9171). Blood, 2021, 138, 3613-3613.	1.4	1
219	Determinants of ten-year overall survival of acute myeloid leukemia: a large national cancer database analysis. Leukemia and Lymphoma, 2022, 63, 939-945.	1.3	1
220	Outcomes of Therapy with Venetoclax Combined with Hypomethylating Agents in Favorable-Risk Acute Myeloid Leukemia (AML). Blood, 2020, 136, 41-42.	1.4	1
221	Hypokalemic Quadriparesis Secondary to Abuse of Cocaine and Heroin. Rhode Island Medical Journal (2013), 2015, 98, 32-3.	0.2	1
222	Association of insurance types and outcomes in acute promyelocytic leukemia. Leukemia and Lymphoma, 2022, 63, 2627-2635.	1.3	1
223	Nasopharyngeal carcinoma in pregnancy: A case series and literature review. Cancer Treatment and Research Communications, 2016, 9, 126-130.	1.7	0
224	Leukemic transformation in patients with myeloproliferative neoplasms: a population-based retrospective study. Future Oncology, 2017, 13, 1239-1246.	2.4	0
225	Haploidentical Transplants for Acute Myeloid Leukemia in Adults. , 2018, , 231-243.		0
226	Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia. Leukemia and Lymphoma, 2019, 60, 246-249.	1.3	0
227	Disparity in utilization of multiagent therapy for acute promyelocytic leukemia (APL): A large National Cancer Database (NCDB) analysis.. Journal of Clinical Oncology, 2021, 39, 6587-6587.	1.6	0
228	Sarcomatoid renal cell carcinoma (SRCC): University of Nebraska Medical Center experience.. Journal of Clinical Oncology, 2013, 31, 472-472.	1.6	0
229	Impact of rituximab on the course of low-grade follicular lymphoma.. Journal of Clinical Oncology, 2013, 31, 8572-8572.	1.6	0
230	Effect of smoking on survival from non-small cell lung cancer.. Journal of Clinical Oncology, 2013, 31, 1570-1570.	1.6	0
231	Exertional Chest Pain and Dyspnea From Hyperviscosity Syndrome Related to Marginal Zone Lymphoma. World Journal of Oncology, 2014, 5, 175-177.	1.5	0
232	Clinicopathologic characteristics and management trends of cutaneous melanoma among older patients: A National Cancer Data Base (NCDB) analysis.. Journal of Clinical Oncology, 2014, 32, 9059-9059.	1.6	0
233	Systemic therapy use in stage IV pancreatic cancer: A population-based analysis using National Cancer Data Base (NCDB).. Journal of Clinical Oncology, 2014, 32, e15190-e15190.	1.6	0
234	Chemotherapy use in stage III colon cancer: A National Cancer Data Base (NCDB) analysis.. Journal of Clinical Oncology, 2014, 32, 3576-3576.	1.6	0

#	ARTICLE	IF	CITATIONS
235	Clinicopathologic Features, Management and Outcomes of Blastoid Variant (BV) of Mantle Cell Lymphoma (MCL): A Nebraska Lymphoma Study Group (NLSG) Experience. <i>Blood</i> , 2014, 124, 2971-2971.	1.4	0
236	Trend in Systemic Therapy Use in Acute Myeloid Leukemia from 2000 to 2011 Using National Cancer Database. <i>Blood</i> , 2014, 124, 2275-2275.	1.4	0
237	Outcomes of primary plasmacytoma (PP) in United States (US).. <i>Journal of Clinical Oncology</i> , 2015, 33, 8597-8597.	1.6	0
238	Acute promyelocytic leukemia (APL) in pregnancy: A systematic review.. <i>Journal of Clinical Oncology</i> , 2015, 33, e18017-e18017.	1.6	0
239	Incidence and survival of chronic myelomonocytic leukemia (CMML) in the United States (US).. <i>Journal of Clinical Oncology</i> , 2015, 33, e18072-e18072.	1.6	0
240	Survival and risk of second primary malignancy (SPM) in essential thrombocythemia (ET): An analysis of the Surveillance, Epidemiology and End Results (SEER) database.. <i>Journal of Clinical Oncology</i> , 2015, 33, e18083-e18083.	1.6	0
241	Impact of hospital volume on outcomes of patients undergoing chemotherapy for acute myeloid leukemia (AML): A matched cohort study.. <i>Journal of Clinical Oncology</i> , 2015, 33, e18067-e18067.	1.6	0
242	The effect of adjuvant radiotherapy on survival in locoregional urothelial malignancies of the upper urinary tract.. <i>Journal of Clinical Oncology</i> , 2015, 33, e15636-e15636.	1.6	0
243	Prognostic role of at-diagnosis positron emission tomography (PET) scan in follicular lymphoma grade 3 (FL3).. <i>Journal of Clinical Oncology</i> , 2015, 33, e19507-e19507.	1.6	0
244	Survival of de novo and secondary acute promyelocytic leukemia: A propensity matched analysis of the Surveillance, Epidemiology and End Results database.. <i>Journal of Clinical Oncology</i> , 2015, 33, 7046-7046.	1.6	0
245	Survival of BCR-ABL positive and negative chronic myeloid leukemia: A propensity matched analysis of the Surveillance, Epidemiology, and End Results database.. <i>Journal of Clinical Oncology</i> , 2015, 33, e18053-e18053.	1.6	0
246	Role of radiation (RT) in primary mediastinal large B-cell lymphoma (PMBCL): An analysis of the Surveillance, Epidemiology, and End Results (SEER) database.. <i>Journal of Clinical Oncology</i> , 2015, 33, 8562-8562.	1.6	0
247	Conditional survival estimates for lung cancer histologic subtypes in the U.S. (2004-2008).. <i>Journal of Clinical Oncology</i> , 2015, 33, 7550-7550.	1.6	0
248	Survival of patients with secondary acute myeloid leukemia (sAML) in Hodgkin Lymphoma (HL): A Surveillance Epidemiology and End Results (SEER) database study.. <i>Journal of Clinical Oncology</i> , 2015, 33, e18049-e18049.	1.6	0
249	Risk of second primary malignancy (SPM) and survival of adult patients with polycythemia vera (PV): A U.S. population-based study.. <i>Journal of Clinical Oncology</i> , 2015, 33, e18081-e18081.	1.6	0
250	Survival of subcutaneous panniculitis-like T-cell lymphoma (SPTCL) and peripheral T-cell lymphoma (PTCL): A propensity matched analysis of the Surveillance, Epidemiology and End Results (SEER) database.. <i>Journal of Clinical Oncology</i> , 2015, 33, 8545-8545.	1.6	0
251	Low molecular weight heparin (LMWH) use in patients with hematologic malignancy-associated venous thromboembolism (VTE) and severe thrombocytopenia.. <i>Journal of Clinical Oncology</i> , 2016, 34, e21588-e21588.	1.6	0
252	Determinants of receipt of hematopoietic cell transplantation (HCT) in younger patients with acute myeloid leukemia (AML).. <i>Journal of Clinical Oncology</i> , 2016, 34, e18027-e18027.	1.6	0

#	ARTICLE	IF	CITATIONS
253	Secondary acute myeloid leukemia (sAML) in patients with myeloproliferative disorder (MPD).. Journal of Clinical Oncology, 2016, 34, e18513-e18513.	1.6	0
254	Risk of 30-Day Mortality and Its Association with Health System and Socioeconomic Factors in Diffuse Large B Cell Lymphoma (DLBCL). Blood, 2016, 128, 2347-2347.	1.4	0
255	Hospital Volume Does Not Influence in-Hospital Mortality of Autologous Hematopoietic Cell Transplant Among Multiple Myeloma Patients in the United States. Blood, 2016, 128, 392-392.	1.4	0
256	Demographic, clinicopathologic and survival differences among left sided versus right sided metastatic colorectal adenocarcinoma.. Journal of Clinical Oncology, 2017, 35, e15068-e15068.	1.6	0
257	Effects of obesity on overall survival (OS) of patients with acute myeloid leukemia (AML).. Journal of Clinical Oncology, 2019, 37, e18510-e18510.	1.6	0
258	Prevalence and Effects of Polypharmacy on Overall Survival (OS) of Acute Myeloid Leukemia (AML). Blood, 2019, 134, 5086-5086.	1.4	0
259	Effect of Using Multiagent Versus Single Agent Chemotherapy on Overall Survival (OS) of Older Adults with Acute Myeloid Leukemia (AML). Blood, 2019, 134, 2155-2155.	1.4	0
260	Usefulness of Charlson comorbidity index (CCI) to predict early mortality and overall survival (OS) in acute myeloid leukemia (AML).. Journal of Clinical Oncology, 2020, 38, e19129-e19129.	1.6	0
261	Myxedema Coma with Reversible Cardiopulmonary Failure: a Rare Entity in 21 Century. MÃ¡dica, 2015, 10, 268-271.	0.1	0
262	Efficacy of Autologous Stem Cell Transplantation in Adult Burkitt/ Burkitt-like Lymphoma: A Systematic Review. Blood, 2021, 138, 4902-4902.	1.4	0
263	Association of Insurance Types and Survival in Acute Promyelocytic Leukemia (APL). Blood, 2021, 138, 4129-4129.	1.4	0
264	Poor Outcomes of Older Adults with Acute Promyelocytic Leukemia (APL) Regardless of Insurance Types. Blood, 2021, 138, 3065-3065.	1.4	0
265	Zella 201: A Biomarker-Guided Phase II Study of Alvocidib Followed By Cytarabine and Mitoxantrone in MCL-1 Dependent Acute Myeloid Leukemia (AML): Results of Newly Diagnosed High-Risk Exploratory Arm. Blood, 2020, 136, 48-50.	1.4	0
266	Early Mortality and Overall Survival in Acute Promyelocytic Leukemia: Do Real-World Data Match Results of the Clinical Trials?. Blood, 2020, 136, 13-14.	1.4	0
267	Prognostic Impact of a Modified European LeukemiaNet (ELN) Genetic Risk Stratification in Predicting Outcomes for Adults with Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (HCT). a Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis for the CIBMTR Acute Leukemia Writing Committee. Blood, 2020, 136, 27-29.	1.4	0
268	Age-Based Probability of Ten-Year Overall Survival (OS) of Acute Myeloid Leukemia (AML): A National Cancer Database (NCDB) Analysis. Blood, 2020, 136, 24-25.	1.4	0
269	Identifying patients with leukemia who are at risk for fungal infections. Clinical Advances in Hematology and Oncology, 2017, 15, 518-520.	0.3	0
270	The Missing LNK: Evolution from Cytosis to Chronic Myelomonocytic Leukemia in a Patient with Multiple Sclerosis and Germline SH2B3 Mutation. Case Reports in Genetics, 2022, 2022, 1-5.	0.2	0

#	ARTICLE	IF	CITATIONS
271	Predicting early mortality and overall survival (OS) in acute promyelocytic leukemia (APL) based on Charlson comorbidity index (CCI).. Journal of Clinical Oncology, 2022, 40, e19017-e19017.	1.6	0
272	Risk of second primary malignancy in patients with primary myelofibrosis: A SEER database study.. Journal of Clinical Oncology, 2022, 40, e19079-e19079.	1.6	0
273	Using Charlson comorbidity index (CCI) to predict outcomes of older patients with acute promyelocytic leukemia (APL).. Journal of Clinical Oncology, 2022, 40, e18751-e18751.	1.6	0
274	Factors Affecting Utilization Of Chemotherapy In Acute Lymphoblastic Leukemia (ALL): A SEER Database Study. International Journal of Cancer Care and Delivery, 2022, 2, .	0.0	0
275	Risk, overall survival, and prognostic analysis of therapy-related acute myeloid leukemia in non-Hodgkin lymphoma survivors.. Journal of Clinical Oncology, 2022, 40, e19037-e19037.	1.6	0